New cholesterol guidelines: Worth the wait?

Cleveland Clinic Journal of Medicine

Volumn 81, Issue 1, 2014, Pages 11-19

  Raymond, Chad ^a   Cho, Leslie ^a   Rocco, Michael ^a,b   Hazen, Stanley L ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE; ATHEROSCLEROSIS; BLOOD; DIABETES MELLITUS; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PRACTICE GUIDELINE; RISK ASSESSMENT;

ADULT; AGE FACTORS; ATHEROSCLEROSIS; CHOLESTEROL, LDL; DIABETES MELLITUS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT;

EID: 84891786883     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.81a.13161     Document Type: Note

References (39)

1. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; published online Nov 13. DOI:10.1016/j.jacc.2013.11.002.
2. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-3421.
3. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227-239.
4. American Heart Association. 2013 Prevention guidelines tools. CV risk calculator. http://my.americanheart.org/professional/StatementsGuidelines/ PreventionGuidelines/Prevention-Guidelines_UCM_457698_SubHomePage.jsp. Accessed December 10, 2013.
5. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol 2009; 29:431-438.
6. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009; 50(suppl):S172-S177.
7. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
8. de Lemos JA, Blazing MA, Wiviott SD, et al; for the A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes. Phase Z of the A to Z trial. JAMA 2004; 292:1307-1316.
9. Downs JR, Clearfield M, Weis S, et al, for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998; 279:1615-1622.
10. Koren MJ, Hunninghake DB, on behalf of the ALLIANCE investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics. J Am Coll Cardiol 2004; 44:1772-1779.
11. Sever PS, Dahlof B, Poulter NR, et al, ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361:1149-1158.
12. Colhoun HM, Betteridge DJ, Durrington PN, et al, on behalf of the CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364:685-696.
13. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001-1009.
14. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
15. Pedersen TR, Faegeman O, Kastelein JJ, et al, Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294:2437-2445.
16. Ridker PM, Danielson E, Fonseca FAH, et al, for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207.
17. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349-1357.
18. Nakamura H, Arakawa K, Itakura H, et al, for the MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin Japan (MEGA Study): a prospective rabndomised controlled trial. Lancet 2006; 368:1155-1163.
19. Schwartz GG, Olsson AG, Ezekowitz MD, et al, Myocardial Ischemia Reduction with Aggreessive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285:1711-1718.
20. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990; 323:946-955.
21. Cannon CP, Braunwald E, McCabe CH, et al, for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-1504.
22. Baigent C, Landray MJ, Reith C, et al, SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377:2181-2192.
23. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425-1435.
24. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301-1308.
25. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1989; 8:1245-1255.
26. AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365:2255-2267.
27. HPS2-Thrive Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013; 34:1279-1291.
28. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 2013; 36(suppl 1):S11-S66.
29. Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Association of Clinical Endocrinologists'comprehensive diabetes management algorithm 2013 consensus statement-executive summary. Endocr Pract 2013; 19:536-557.
30. Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet 2013 doi: 10.1016/S0140-6736(13)62388-0. [Epub ahead of print]
31. The ARIC investigators. The Atherosclerosis Risk in Communities (ARIC) study: design and objectives. Am J Epidemiol 1989; 129:687-702.
32. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991; 1:263-276.
33. Friedman GD, Cutter GR, Donahue RP, et al. CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol 1988; 41:1105-1116.
34. Dawber TR, Kannel WB, Lyell LP. An approach to longitudinal studies in a community: the Framingham study. Ann N Y Acad Sci 1963; 107:539-556.
35. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol 1979; 110:281-290.
36. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352:1293-1304.
37. Belancer C, Buring JE, Cook N, et al, The Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321:129-135.
38. Langer R, White E, Lewis C, et al. The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol 2003; 13:S107-S121.
39. Strong JP, Malcom GT, Oalmann MC, Wissler RW. The PDAY study: natural history, risk factors, and pathobiology. Ann N Y Acad Sci 1997; 811:226-235.